1 not yet recruiting, 1 recruiting, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow Resectable Colorectal Carcinoma: new trials by email Literature Review of Resectable Colorectal Carcinoma trials Research Report on Resectable Colorectal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 2 | Not yet recruiting | Mayo Clinic | 80 | 2026-12-01 | 2026-10-05 |
| Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) Trastuzumab deruxtecan, Durvalumab, Panitumumab - Colorectal Cancer, Resectable Colorectal Carcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 197 | 2023-05-11 | 2026-09-11 |
| Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 2 | Terminated | M.D. Anderson Cancer Center | 29 | 2016-09-23 | 2026-02-17 |
Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Rectal Diseases (3)
Biopsy (1) · Drug Therapy (1) · Embolization, Therapeutic (1) · Hepatectomy (1) · Magnetic Resonance Spectroscopy (1) · Metastasectomy (1) · Nivolumab (1) · Panitumumab (1) · Specimen Handling (1) · amivantamab (1) · balstilimab (1) · durvalumab (1) · sotorasib (1) · trastuzumab deruxtecan (1)
Gruppo Oncologico del Nord-Ovest (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (2) · Italy (1)
Filippo Pietrantonio, MD (1) · Scott L. Nyberg, MD, PhD (1) · Yun S Chun (1)
R01DK140085 (1)